12.6
Experimentos cruzados
Los experimentos cruzados, también llamados diseño de mediciones repetidas, son un diseño de estudio en el que todas las unidades experimentales están…
Un diseño de estudio cruzado también se denomina diseño de mediciones repetidas, donde las unidades experimentales reciben todos los tratamientos en diferentes períodos.
Por ejemplo, considere un ensayo clínico que compara el medicamento A y el medicamento B en 10 pacientes asmáticos divididos aleatoriamente en el grupo uno y el grupo dos.
En primer lugar, cada grupo recibe diferentes fármacos durante dos semanas, registrando su efecto en la fisiología del paciente. A esto le sigue un período de lavado, para eliminar el medicamento del cuerpo del paciente.
Ahora, los grupos se intercambian para que el segundo grupo reciba el fármaco A y el primer grupo reciba el fármaco B. Esto se denomina diseño cruzado. En este diseño, los sujetos actúan como sus propios controles, y sus características no se modifican a lo largo del estudio. También elimina las variabilidades entre sujetos.
Este diseño se utiliza generalmente en ensayos clínicos de fase tardía con fármacos que ayudan a controlar los síntomas y no a curarlos por completo.
Por ejemplo, en el ejemplo anterior, el fármaco B no tendrá la oportunidad de demostrar su eficacia si el fármaco A cura al paciente durante el primer período.
View the full transcript and gain access to JoVE Core videos
Q1: What is a crossover experiment and how does it differ from other study designs?
A crossover experiment, also called a repeated measurements design, exposes all experimental units to every treatment across different time periods. Unlike simple randomized trials, subjects act as their own controls, eliminating inter-subject variability. This approach is particularly valuable in clinical trials where patients receive all treatments sequentially, with washout periods between exposures to clear previous treatments from the body.
Q2: Why is a washout period necessary in crossover studies?
A washout period eliminates residual effects of the previous treatment from the subject's body before introducing the next treatment. This prevents carryover effects that could confound results and compromise data validity. Without adequate washout time, the lingering effects of one drug could artificially influence responses to the subsequent treatment, making it impossible to isolate each treatment's true effect.
Q3: When are crossover designs most appropriate in pharmaceutical research?
Crossover designs are ideal for late-phase clinical trials testing drugs that control symptoms rather than cure diseases completely. They work well for comparing bioavailability or drug ingestion in the human body against reference drugs. However, crossover designs are unsuitable for chronic, stable diseases or when drugs provide complete cures, as treatment effects would prevent meaningful comparison of subsequent treatments.
Q4: How do subjects serve as their own controls in crossover experiments?
In crossover designs, each subject receives all treatments sequentially, allowing researchers to compare treatment effects within the same individual. Since subjects' characteristics remain constant throughout the study, differences in outcomes directly reflect treatment effects rather than individual variation. This internal comparison eliminates confounding variables associated with inter-subject differences, making crossover designs more statistically powerful than between-subject comparisons.
Q5: What are the advantages of using crossover designs with smaller sample sizes?
Crossover designs require smaller sample sizes than simple randomized trials because each subject provides data for all treatment conditions. Since subjects act as their own controls, researchers can detect treatment differences more efficiently with fewer participants. This efficiency makes crossover designs cost-effective and practical in fields like psychology, pharmaceuticals, agriculture, and medicine where sample recruitment may be limited.
Q6: What is an example of how crossover experiments work in clinical drug trials?
In a typical example, asthmatic patients are randomly divided into two groups. Group one receives drug A for two weeks while group two receives drug B, with effects recorded. After a washout period, the groups switch treatments. This design allows researchers to compare both drugs' effectiveness within the same patients, ensuring fair comparison while controlling for individual patient characteristics that might influence drug response.
Q7: Why are crossover designs unsuitable for studying chronic diseases?
Crossover designs fail for chronic, stable diseases because if the first treatment cures or substantially improves the condition, the disease may not return during the washout period. This prevents meaningful evaluation of subsequent treatments. For example, if drug A cures asthma in the first period, drug B cannot demonstrate its effectiveness in the second period, making treatment comparison impossible and invalidating the study's conclusions.